Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine

Recruiting now · Not applicable

Conditions studied: Ulcerative Colitis

In brief

To evaluate the possible efficacy and safety of mebendazole in patients with ulcerative colitis treated with mesalamine

Key facts

Study ID

NCT06335160

Run by

Tanta University

People needed

46

Starts

2024-04-20

Expected to finish

2026-05-01

Last updated by the study team

2026-02-06

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years old Both male and female will be included Mild and moderate UC patients diagnosed and confirmed by endoscope Patient treated with 5-aminosalislic acid (mesalamine)

You may not qualify if…

• - Patients with severe UC
• Significant liver and kidney function abnormalities
• Diabetic patients
• Patients with Colorectal cancer patients
• Patients taking rectal or systemic steroids
• Patients on immunosuppressants or biological therapies
• Addiction to alcohol and / or drugs
• Known allergy to the studied medications
• History of complete or partial colectomy.
• Patients with congestive heart failure, other heart disease (arrhythmia, ischemic heart disease including angina and myocardial infarction).
• Patients with other inflammatory diseases and active infection.
• Patients with stressful condition (COPD, morbid obesity).
• Patients with liver disease.
• Patients with thrombocytopenia and neutropenia.
• Patients with any type of seizures (case report for mebendazole induced convulsion).
• Patients with renal disease (case report for mebendazole induced nephrotoxicity).
• Patients with coagulation disorders.
• Patients on metronidazole (to avoid Stevens-Johnson syndrome).
• Patients with hypersensitivity to mebendazole, albendazole or benzimidazole
• Patients using antioxidants.
• Pregnant and lactating females.
• Patients receiving, metronidazole, warfarin, low dose of aspirin, clopidogril, enzyme inducers (phenytoin, carbamazepine) and inhibitors (valoproate) to avoid potential pharmacodynamics and pharmacokinetic interactions.

Where it is running

• Tanta Unuversity — Tanta, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.